Cannabinoids showed limited benefit for chronic primary pain in short-term studies
A meta-analysis of 8 randomized trials found cannabinoids did not significantly reduce chronic primary pain overall, but treatment lasting more than 4 weeks showed significant pain reduction.
Quick Facts
What This Study Found
Across 8 RCTs with 240 patients, VAS pain reduction was not significant for cannabinoids vs placebo (MD -0.64, CI -1.30 to 0.02). However, studies with more than 4 weeks of treatment showed significant pain reduction (MD -1.28, CI -2.33 to -0.22). No significant differences were found for fibromyalgia impact, anxiety, depression, or discontinuation due to adverse events.
Key Numbers
8 RCTs, 240 patients. Overall pain: MD -0.64, non-significant. Over 4 weeks: MD -1.28, significant. FIQ, anxiety, depression: non-significant. Evidence quality generally low.
How They Did This
Systematic review and meta-analysis searching PubMed, EMBASE, and Cochrane through October 2021. Included 8 RCTs (4 parallel, 4 crossover) with 240 chronic primary pain patients. Evidence quality assessed using GRADE.
Why This Research Matters
Chronic primary pain (including fibromyalgia and other conditions) affects millions. This meta-analysis suggests cannabinoids may need longer treatment periods to show benefit.
The Bigger Picture
The finding that longer treatment produced significant pain relief suggests cannabinoids may have a gradual onset of benefit for chronic primary pain, unlike acute analgesics.
What This Study Doesn't Tell Us
Very small total sample (240 patients). Generally low-quality evidence due to imprecision and bias risk. Heterogeneous pain conditions grouped under "chronic primary pain."
Questions This Raises
- ?What is the optimal treatment duration for cannabinoids in chronic pain?
- ?Would larger trials confirm the longer-term benefit signal?
Trust & Context
- Key Stat:
- Significant pain relief only after 4+ weeks of treatment
- Evidence Grade:
- Systematic meta-analysis, but very small sample sizes and generally low-quality underlying evidence.
- Study Age:
- Published in 2022 with studies searched through October 2021.
- Original Title:
- Systematic Review and Meta-analysis Seem to Indicate that Cannabinoids for Chronic Primary Pain Treatment Have Limited Benefit.
- Published In:
- Pain and therapy, 11(4), 1341-1358 (2022)
- Authors:
- Giossi, Riccardo(2), Carrara, Federica, Padroni, Matteo, Bilancio, Maria Concetta, Mazzari, Martina, Enisci, Silvia, Romio, Maria Silvia, Boni, Gloria, Corrù, Federica, Fittipaldo, Veronica Andrea, Tramacere, Irene, Pani, Arianna, Scaglione, Francesco, Fornasari, Diego
- Database ID:
- RTHC-03874
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Do cannabinoids help chronic pain?
Overall results were not statistically significant, but studies lasting more than 4 weeks did show significant pain reduction, suggesting cannabinoids may need time to build therapeutic effects.
Why were the results inconclusive?
Only 240 patients across 8 small trials were available. The evidence quality was generally low, and most studies were too short to capture potential longer-term benefits.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03874APA
Giossi, Riccardo; Carrara, Federica; Padroni, Matteo; Bilancio, Maria Concetta; Mazzari, Martina; Enisci, Silvia; Romio, Maria Silvia; Boni, Gloria; Corrù, Federica; Fittipaldo, Veronica Andrea; Tramacere, Irene; Pani, Arianna; Scaglione, Francesco; Fornasari, Diego. (2022). Systematic Review and Meta-analysis Seem to Indicate that Cannabinoids for Chronic Primary Pain Treatment Have Limited Benefit.. Pain and therapy, 11(4), 1341-1358. https://doi.org/10.1007/s40122-022-00434-5
MLA
Giossi, Riccardo, et al. "Systematic Review and Meta-analysis Seem to Indicate that Cannabinoids for Chronic Primary Pain Treatment Have Limited Benefit.." Pain and therapy, 2022. https://doi.org/10.1007/s40122-022-00434-5
RethinkTHC
RethinkTHC Research Database. "Systematic Review and Meta-analysis Seem to Indicate that Ca..." RTHC-03874. Retrieved from https://rethinkthc.com/research/giossi-2022-systematic-review-and-metaanalysis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.